Bruno Fuchs
Overview
Explore the profile of Bruno Fuchs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
2394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elyes M, Heesen P, Schelling G, Bode-Lesniewska B, Studer G, Fuchs B, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941878
Sarcomas are rare mesenchymal tumors with significant heterogeneity, encompassing both bone and soft tissue neoplasms that can range from benign to malignant and from superficial to deep-seated lesions [...].
2.
Jeys L, Morris G, Kurisunkal V, Botello E, Boyle R, Ebeid W, et al.
Bone Joint J
. 2025 Jan;
107-B(2):246-252.
PMID: 39889743
Aims: The Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma....
3.
Heesen P, Di Lonardo M, Ciobanu-Caraus O, Schelling G, Zwahlen D, Bode-Lesniewska B, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682249
The historically most commonly used preoperative radiotherapy regimen for soft tissue sarcomas (STSs) consists of 50 Gray (Gy) delivered in 25 fractions over 5 weeks, achieving excellent local control, but...
4.
Jaeger R, Mosku N, Paganini D, Schelling G, van Oudenaarde K, Falkowski A, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682090
This study evaluates the effectiveness of communication strategies and pain management protocols to enhance patients' experiences during sarcoma core biopsies. Recognizing the complexity and anxiety associated with sarcoma diagnoses, this...
5.
Fuchs B, Heesen P
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518639
The transformation of healthcare from a fee-for-service model to value-based care is particularly crucial in managing complex and rare diseases like sarcoma, where data fragmentation and variability present significant challenges....
6.
Scharer M, Hosli P, Heesen P, Schelling G, Obergfell T, Nydegger K, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518055
This study evaluated the impact of care pathways on the incidence of local recurrence (LR) in patients with soft tissue sarcomas (STS) and identified factors predictive of LR. It compared...
7.
Nydegger K, Obergfell T, Heesen P, Schelling G, Studer G, Bode-Lesniewska B, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410028
Background: Sarcomas, a diverse group of malignant tumors arising from mesenchymal tissues, pose significant diagnostic and therapeutic challenges. This study compares the outcomes of planned resections (PEs) and unplanned resections...
8.
Mattmann A, Glanzmann C, Fuchs B, Bode B, Studer G
Adv Radiat Oncol
. 2024 Sep;
9(10):101562.
PMID: 39314903
Purpose: Normofractionated preoperative radiation therapy (nRT) with 50 Gy applied in 25 fractions represents the most widely used radiation therapy (RT) regimen in combined local treatment of soft tissue sarcomas...
9.
Heesen P, Schelling G, Birbaumer M, Jager R, Bode B, Studer G, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061155
This manuscript examines the synergistic potential of prospective real-world/time data/evidence (RWTD/E) and randomized controlled trials (RCTs) to enrich healthcare research and operational insights, with a particular focus on its impact...
10.
Obergfell T, Nydegger K, Heesen P, Schelling G, Bode-Lesniewska B, Studer G, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001505
This study follows the Target Trial Emulation (TTE) framework to assess the impact of unplanned resections (UEs) and planned resections (PEs) of sarcomas on local recurrence-free survival (LRFS), metastasis-free survival...